Create Free Account

By creating account you will get access to hot stocks & personalised emails

Invion Ltd

Healthcare AU IVX

0.0055AUD
0.0005(10.00%)

Last update at 2024-05-16T00:00:00Z

Day Range

0.00550.0055
LowHigh

52 Week Range

0.0040.008
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.61482M -2.24138M -1.48295M -0.95389M -2.54621M
Minority interest - - - - -
Net income -1.61482M -2.24138M -1.48295M -0.95389M -1.09292M
Selling general administrative 1.62M 2.40M 1.79M 2.35M 2.81M
Selling and marketing expenses - - - - -
Gross profit 1.21M 0.97M 0.81M 1.92M 3.88M
Reconciled depreciation 0.68M 0.42M 0.28M 0.28M 0.31M
Ebit -1.64847M -2.32143M -1.57234M -1.02646M -2.51738M
Ebitda -0.96537M -1.89901M -1.29447M -0.74856M -2.20781M
Depreciation and amortization 0.68M 0.42M 0.28M 0.28M 0.31M
Non operating income net other - - - - -
Operating income -1.64847M -2.24143M -1.57234M -1.02646M -2.51738M
Other operating expenses 0.04M 0.89M 0.77M 1.31M 6.40M
Interest expense - 0.00005M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.03M 0.00005M 0.00009M 0.00457M 0.03M
Net interest income 0.03M 0.00005M 0.00009M 0.00055M 0.00133M
Extraordinary items - - - 0.00000M 1.48M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M -0.00005M -0.00009M -0.00055M -1.45328M
Total revenue 4.10M 3.29M 2.33M 3.48M 3.88M
Total operating expenses 5.75M 5.61M 3.90M 4.50M 6.40M
Cost of revenue 2.90M 2.32M 1.52M 1.56M 2.26M
Total other income expense net 0.08M 0.08M 0.09M 0.07M -0.02882M
Discontinued operations - - - - 1.48M
Net income from continuing ops -1.61482M -2.24138M -1.48295M -0.95389M -2.54621M
Net income applicable to common shares -1.61482M -2.24138M -1.48295M -0.95389M -1.06410M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 19.05M 20.04M 5.64M 5.76M 6.06M
Intangible assets 13.23M 11.39M 4.57M 4.84M 5.12M
Earning assets - - - - -
Other current assets - 0.03M 0.03M 0.03M 0.05M
Total liab 0.65M 0.46M 0.85M 0.33M 0.60M
Total stockholder equity 18.40M 19.58M 4.79M 5.43M 5.46M
Deferred long term liab - - - - -
Other current liab 0.25M 0.24M 0.40M 0.22M 0.25M
Common stock 146.88M 146.54M 130.96M 130.56M 130.56M
Capital stock 146.88M 146.54M 130.96M 130.56M 130.56M
Retained earnings -130.47522M -130.83604M -128.59466M -127.11171M -148.21801M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 4.08M 8.47M 1.04M 0.62M 0.77M
Cash and equivalents - 8.47M 1.04M - -
Total current liabilities 0.65M 0.46M 0.85M 0.33M 0.60M
Current deferred revenue - - 0.01M 0.01M 0.05M
Net debt -4.08490M -8.47344M -1.03682M -0.61884M -0.77131M
Short term debt - 0.00000M -0.01100M -0.01100M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity -16.40793M -15.70762M -2.36146M -3.44372M 23.12M
Property plant equipment 0.06M 0.00048M 0.00102M 0.00389M 0.00482M
Total current assets 5.76M 8.65M 1.08M 0.92M 0.94M
Long term investments - - - - -
Net tangible assets 5.17M 8.19M 0.23M 0.59M 0.34M
Short term investments - - - - -
Net receivables 1.62M 0.14M 0.01M 0.27M 0.12M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.40M 0.22M 0.45M 0.11M 0.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.99M 3.87M 2.43M 1.99M 23.12M
Additional paid in capital - - - - -
Common stock total equity - - - 130.56M 130.56M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -13.28633M -11.39360M -4.56602M -4.84389M 5.12M
Deferred long term asset charges - - - - -
Non current assets total 13.29M 11.39M 4.57M 4.84M 5.12M
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -2.57583M -7.25000M - - -0.01361M
Change to liabilities 0.16M -0.38907M 0.49M -0.30285M -1.14779M
Total cashflows from investing activities -2.57583M -7.25000M -7.25000M -7.25000M -0.01361M
Net borrowings - - - - -
Total cash from financing activities 15.80M 15.80M 15.80M 15.80M 15.80M
Change to operating activities 0.02M 0.02M -0.01825M -0.02978M -0.03769M
Net income -1.61482M -2.24138M -1.48295M -0.95389M -1.06410M
Change in cash -4.38854M 7.44M 0.42M -0.15247M -2.12006M
Begin period cash flow 8.47M 1.04M 0.62M 0.77M 2.89M
End period cash flow 4.08M 8.47M 1.04M 0.62M 0.77M
Total cash from operating activities -1.81270M -1.10890M 0.42M -0.15247M -2.10569M
Issuance of capital stock - 16.64M - - -
Depreciation 0.68M 0.42M 0.28M 0.28M 0.31M
Other cashflows from investing activities - - 0.00000M 0.00000M -0.00755M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -1.50149M -0.13798M 0.25M -0.11367M -0.00146M
Sale purchase of stock -0.84198M -0.84198M -0.84198M - -
Other cashflows from financing activities -2.57583M -7.25000M -7.25000M -0.84198M -0.01361M
Change to netincome 0.43M 1.21M 0.90M 0.93M -0.16423M
Capital expenditures 2.58M 7.25M 7.25M 0.08M 0.00605M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.50149M -0.13798M 0.25M -0.11367M 0.00133M
Stock based compensation 0.37M 0.96M 0.90M 0.93M -
Other non cash items -0.88099M 0.71M 1.62M 0.52M 0.75M
Free cash flow -4.38854M -8.35890M 0.42M -0.15247M -0.00605M

Fundamentals

  • Previous Close 0.005
  • Market Cap32.12M
  • Volume300000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.81122M
  • Revenue TTM4.39M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 1.21M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IVX
Invion Ltd		 0.0005 10.00% 0.0055 - - 7.32 1.98 7.61 -41.1654
AFP
AFT Pharmaceuticals Ltd		 -0.04 1.60% 2.46 27.33 17.06 1.79 4.41 2.18 16.66
PBP
Probiotec Ltd		 -0.06 2.03% 2.90 29.20 - 1.06 2.64 1.39 8.58
VLS
Vita Life Sciences Ltd		 -0.03 1.35% 2.19 12.88 - 1.73 2.97 1.41 7.98
NXS
Next Science Ltd		 -0.04 10.67% 0.34 - 128.21 4.47 5.03 3.90 -5.9908

Reports Covered

Stock Research & News

View All

Profile

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Invion Ltd

100 Albert Road, Melbourne, VIC, Australia, 3205

Key Executives

Name Title Year Born
Mr. Thian Chew Exec. Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Chief Financial Officer 1973
Dr. Dean Naylor Head of Intellectual Property Devel. NA
Ms. Claire Newstead-Sinclair BBus, C.A., CA Company Sec. NA
Mr. Thian Chew Executive Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Chief Financial Officer 1973
Dr. Dean Naylor Head of Intellectual Property Development NA
Ms. Claire Newstead-Sinclair BBus, C.A., CA Company Secretary NA
Mr. Thian Chew Executive Chairman & CEO NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Chief Financial Officer 1973

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.